Practice Contact Information
1229 E. Seminole Street, Suite 520
Web Site: https://www.mercy.net/doctor/a-daniel-pinheiro-md/
Areas of Interest in Head and Neck Surgery
Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon
I am proud to be part of an organization whose mission statement is to “… bring to life the healing ministry of Jesus through our compassionate care and exceptional service.” Compassionate care and exceptional service are the hallmark of our comprehensive, holistic and multidisciplinary care of those touched by tumors of the thyroid , parathyroid and the head and neck.
The following trials are currently available through CRO (Cancer Research of the Ozarks):
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID (DNA)
A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
A PHASE 2 STUDY OF EFATUTAZONE, AN ORAL PPAR AGONIST, IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED ANAPLASTIC THYROID CANCER
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
ECOG-ACRIN EA 6134 – Randomizes between Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression or Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at progression. BRAF V600 mutation is required, and patients must have Stage IV or unresectable Stage III, measurable disease.
SWOG S1320 – Randomizes between intermittent versus continuous dosing of Dabrafenib + Trametinib for BRAF V600E/K mutant, Stage IV or unresectable Stage III, melanoma. Again, patients must have measurable disease.
SWOG S1616 – Randomizes between Nivolumab + Ipilimumab or Ipilimumab alone in Stage IV or unresectable Stage III melanoma patients with measurable disease refractory to Anti-PD-1 or Anti-PD-L1 agents.
SWOG S1512 – Phase II trial of PD-1 blockade with Pembrolizumab in resectable or unresectable desmoplastic melanoma. Also requires measurable disease
SWOG S1607 – Phase II trial combining T-VEC (talimogene laherparepvec) + Pembroluzumab in patients with in Stage IV or unresectable Stage III melanoma patients with measurable disease who have progressed on Anti-PD1/L1 based therapy. Patients must have 2 cutaneous, subcutaneous or nodal lesions which are injectable.
Pinheiro AD (2002) Parotid neoplasms: the lump near the mandible? Current Surgery 59:509-517.
Pinheiro AD, Foote RL, McCaffrey TV, Kasperbauer JL, Bonner JA, Olsen KD, Cha S, Sargent D
- Intraoperative radiotherapy for head and neck and skull base cancer. Head and Neck,
Boahene DK, Olsen KD, Lewis JE, Pinheiro AD, Pankratz VS, Bagniewski SM (2004)
Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience.
Arch Otolaryngol Head Neck Surg. 130(7):849-56.
Kay PA, Pinheiro AD, Lohse CM, Pankratz VS, Olsen KD, Lewis JE, Nascimento AG. (2004)
Desmoplastic melanoma of the head and neck: histopathologic and immunohistochemical
study of 28 cases. Int J Surg Pathol. 2004 12(1):17-24
Shashy RG, Pinheiro AD, Olsen KD (2006) Toxoplasmosis lymphadenitis presenting as a parotid
mass: a report of 2 cases. Ear Nose Throat J. 2006 Oct;85(10):666-8
Pinheiro AD (2015) Oropharynx cancer: a sexually transmitted disease? Journal of the Greene
County Medical Society, 73(1):8-9.
Pinheiro AD, Kramar RW (2016) Determinants of Cost in the Treatment of T1-T3 Oropharynx
Cancer. International journal of radiation oncology, biology, physics 94(4):866